New York, June 09, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Male Hypogonadism Global Market Report 2023" - https://www.reportlinker.com/p06466493/?utm_source=GNW
, AbbVie Inc, Perrigo Company plc, AstraZeneca PLC, IBSA Institut Biochimique SA, Juniper Laboratories SA, and Sun Pharmaceutical Industries Limited.
The global male hypogonadism market is expected to grow from $3.32 billion in 2022 to $3.55 billion in 2023 at a compound annual growth rate (CAGR) of 7.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The male hypogonadism market is expected to reach $4.48 billion in 2027 at a CAGR of 6.0%.
The male hypogonadism market includes revenues earned by entities through hormone testing, semen analysis, pituitary imaging, genetic studies, and testicular biopsy.The market value includes the value of related goods sold by the service provider or included within the service offering.
Only goods and services traded between entities or sold to end consumers are included.
Male hypogonadism is a disease in which the body produces insufficient amounts of the hormone testosterone. Testosterone is the primary male sex hormone and is essential for the development and growth of men throughout puberty.
North America was the largest region in the male hypogonadism market in 2022.Asia-Pacific is expected to be the fastest-growing region in the forecast period.
The regions covered in male hypogonadism report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the male hypogonadism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The main types of male hypogonadism are klinefelter syndrome, kallmann syndrome, pituitary disorders, and others.Klinefelter syndrome refers to a hereditary disorder that develops in boys when they have an extra copy of the X chromosome at birth.
The drugs are delivered through topical gels, injectable, transdermal patches, and others for testosterone therapy, and gonadotropin-releasing hormone therapy.
The increase in infertility rates is expected to propel the growth of the male hypogonadism market going forward.Infertility refers to a condition affecting the male or female reproductive system that is characterized by the inability to conceive after 12 months or longer of frequent, unprotected sexual activity.
Male hypogonadism, which can lead to decreased sperm production and infertility, is one of the potential causes of male infertility.As a result, the increasing prevalence of male infertility is expected to drive the growth of the male hypogonadism market.
For instance, in October 2021, according to the Office for National Statistics, a UK-based statistics authority, in England and Wales, there were 613,936 live births in 2020, a significant 4.1% drop from 2019. In 2020, the total fertility rate (TFR) fell to a historic low of 1.58 children per woman. As a result, the infertility rate increased from 2019 to 2020. Also, according to a 2021 study published by the Libyan Journal of Medical Sciences, around 70% of infertility is attributed to male factors in Libya. Therefore, an increase in the infertility rate is driving the growth of the male hypogonadism market.
Product innovations are a key trend gaining popularity in the male hypogonadism market.Companies operating in the male hypogonadism market are innovating new products to sustain their position in the market.
For instance, in June 2022, Halozyme, a US-based biotechnology company, launched Tlando, an oral treatment for testosterone replacement therapy of male hypogonadism.Tlando is a prescription drug that contains testosterone, and it is the first oral testosterone treatment approved by FDA.
It is used to treat adult men who, as a result of certain medical disorders, have low or no testosterone.
In July 2022, Gruenenthal, a Germany-based pharmaceutical company acquired Nebido from Bayer AG for €500 million ($551.32 million). This acquisition aimed at improving Gruenenthal’s profitability, allowing it to invest in research and development and create the next generation of pain therapies. Bayer AG is a Germany-based pharmaceutical company operating in the male hypogonadism treatment.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The male hypogonadism market research report is one of a series of new reports that provides male hypogonadism market statistics, including male hypogonadism industry global market size, regional shares, competitors with a male hypogonadism market share, detailed male hypogonadism market segments, market trends, and opportunities, and any further data you may need to thrive in the male hypogonadism industry. This male hypogonadism market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Read the full report: https://www.reportlinker.com/p06466493/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
